Microbot Medical has reported revenue and new customer growth of more than 100% in the second quarter of the 2026 fiscal year, which ended June 30, compared with the first quarter.
This follows the full market release of its Liberty Endovascular Robotic System on April 13.
New health system customers in the second quarter included systems in Massachusetts, North Carolina, Michigan, and Pennsylvania. Microbot also entered into an agreement with Lovell Government Services to serve federal healthcare systems including the Veterans Health Administration, the Military Health System, and the Indian Health Service.
The company expanded its U.S. sales territories from four to eight during the second quarter and said it is on track to reach 12 territories by the end of 2026. The Liberty System also received marketing clearance from the Israeli Ministry of Health, making Israel the first country outside the U.S. to approve the system, according to Microbot.
